Haemonetics Corp (NYSE:HAE) Executive Vice President and Chief Technology Officer, Anila Lingamneni, has sold a total of 2,215 shares of company stock on July 11 and July 12, according to recent SEC filings. The transactions were executed at a uniform price of $90.00 per share, amounting to a total value of $199,350.
The sales were conducted under a pre-arranged 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading. Such plans are typically set up when the insider does not have material non-public information, and the transactions are carried out automatically according to the plan's schedule.
On the first day, Lingamneni sold 2,136 shares, followed by a smaller sale of 79 shares the next day. Following these transactions, Lingamneni's direct ownership in Haemonetics Corp includes 21,331 shares. It's important to note that this figure also comprises unvested restricted stock units that were previously reported.
Haemonetics Corp, headquartered in Boston, Massachusetts, specializes in the development and manufacturing of products in the surgical and medical instruments sector. The recent transactions by a top executive may be of interest to current and potential investors, as insider sales can sometimes provide insights into an executive's view of the company's current valuation or future prospects.
Investors often monitor insider transactions as part of their analysis, considering them alongside other factors when making investment decisions. The disclosed sales by EVP Anila Lingamneni are now public record, providing transparency into the trading activities of Haemonetics' executives.
In other recent news, Haemonetics Corporation has seen significant developments. Needham recently upgraded Haemonetics stock from Hold to Buy, based on the firm's confidence in the company meeting its "high-20%" operating margin target for fiscal year 2026. This confidence stems from expected shifts in the company's gross margin due to changes in Plasma and Interventional Technologies sales.
Haemonetics has also upsized its private offering to $600 million in convertible senior notes, a substantial increase from the initially proposed $525 million. The company has granted initial purchasers a 13-day option to buy up to an additional $100 million principal amount of notes, potentially raising the total offering to $700 million.
The company has reported robust results for its fourth-quarter and full fiscal year 2024, showcasing a 10% organic revenue increase in Q4 and a 12% rise for the fiscal year. Meanwhile, Hafnia Limited's Q1 earnings per share fell slightly short of analyst expectations, reporting a Q1 EPS of $0.43, $0.01 below the consensus estimate. However, Hafnia's revenue for the quarter was robust, significantly surpassing the consensus estimate. These are the recent developments for both companies.
InvestingPro Insights
Amidst the recent insider transactions at Haemonetics Corp (NYSE:HAE), investors may find additional context through key financial metrics and expert analysis. Haemonetics, with a market capitalization of approximately $4.6 billion, is trading at a high earnings multiple, with a current P/E ratio of 39.03. This valuation is based on the last twelve months as of Q4 2024 and reflects a significant premium relative to near-term earnings growth, as the PEG ratio for the same period stands at 17.59.
Despite the high earnings multiple, Haemonetics has demonstrated solid financial health in other areas. With a revenue growth of 12.01% over the last twelve months as of Q4 2024, the company is showing a positive trajectory in its top-line performance. Additionally, Haemonetics has maintained a gross profit margin of 54.38%, indicating strong profitability relative to its revenue.
From an operational standpoint, Haemonetics' cash flows can sufficiently cover interest payments, and its liquid assets exceed short-term obligations, which may reassure investors of the company's financial stability. Moreover, the stock generally trades with low price volatility, which could be appealing to risk-averse investors.
For those considering an investment in Haemonetics or seeking to understand the recent insider selling, there are 6 additional InvestingPro Tips available that could provide further insights into the company's performance and valuation. These tips, along with real-time metrics and analysis, can be found at: https://www.investing.com/pro/HAE. To access these exclusive insights, use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.